Login / Signup

Real-life experience with inotersen in hereditary transthyretin amyloidosis with late-onset phenotype: Data from an early-access program in Italy.

Marco LuigettiGiovanni AntoniniAndrea Di PaolantonioLuca GentileMarina GrandisLuca LeonardiAlessandro LozzaFiore ManganelliAnna MazzeoRoberta MussinelliFilomena MyLaura ObiciElena Maria PennisiViviana NocitiMassimo RussoMario SabatelliAlessandro SalvalaggioMatteo TagliapietraStefano Tozza
Published in: European journal of neurology (2022)
The long-term safety profile of inotersen is favorable. Neurologic disease severity at baseline is the main factor associated with progression.
Keyphrases
  • late onset
  • early onset
  • quality improvement
  • electronic health record
  • big data
  • multiple myeloma
  • wild type
  • data analysis
  • machine learning
  • deep learning